First-line alectinib for ALK-positive lung cancer: is there room for further improvement? by Alfredo Addeo, Giulio Metro

Connect to this object online.

Management of stage III non-small-cell lung cancer: rays of hope by Floryane Kim, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender

Connect to this object online.

Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review by Laure Thouvenin, Timothée Olivier, Giuseppe Banna, Alfredo Addeo, Alex Friedlaender

Connect to this object online.

Oncogenic alterations in advanced NSCLC: a molecular super-highway by Alex Friedlaender, Maurice Perol, Giuseppe Luigi Banna, Kaushal Parikh, Alfredo Addeo

Connect to this object online.

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm by Giuseppe Luigi Banna, Ornella Cantale, Melissa Bersanelli, Marzia Del Re, Alex Friedlaender, Alessio Cortellini, Alfredo Addeo

Connect to this object online.

Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation by Julie Terzic, Amanda Seipel, Jean Dubuisson, Jean-Christophe Tille, Petros Tsantoulis, Alfredo Addeo, S.Intidhar Labidi-Galy

Connect to this object online.

Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma by Giulio Metro, Diego Signorelli, Elio G. Pizzutilo, Laura Giannetta, Giulio Cerea, Miriam Garaffa, Alex Friedlaender, Alfredo Addeo, Martina Mandarano, Guido Bellezza, Fausto Roila

Connect to this object online.